MA50254A - Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido - Google Patents
Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'idoInfo
- Publication number
- MA50254A MA50254A MA050254A MA50254A MA50254A MA 50254 A MA50254 A MA 50254A MA 050254 A MA050254 A MA 050254A MA 50254 A MA50254 A MA 50254A MA 50254 A MA50254 A MA 50254A
- Authority
- MA
- Morocco
- Prior art keywords
- ido
- prophylactic
- expression
- therapeutic agent
- diseases involving
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017178247 | 2017-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50254A true MA50254A (fr) | 2020-07-22 |
Family
ID=65723397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050254A MA50254A (fr) | 2017-09-15 | 2018-09-14 | Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200281904A1 (fr) |
| EP (1) | EP3682900A4 (fr) |
| JP (1) | JP6931067B2 (fr) |
| KR (1) | KR102403289B1 (fr) |
| CN (1) | CN111107876A (fr) |
| AU (1) | AU2018333751B2 (fr) |
| BR (1) | BR112020005100A2 (fr) |
| CA (1) | CA3075870A1 (fr) |
| MA (1) | MA50254A (fr) |
| MX (1) | MX2020002886A (fr) |
| PH (1) | PH12020500510A1 (fr) |
| RU (1) | RU2020113456A (fr) |
| SG (1) | SG11202002316PA (fr) |
| TW (1) | TWI733055B (fr) |
| WO (1) | WO2019054465A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021024393A1 (fr) * | 2019-08-06 | 2021-02-11 | 大鵬薬品工業株式会社 | Polythérapie anticancéreuse mettant en oeuvre un composé azabicyclique et un inhibiteur de la polyadénosine-5'-diphosphate ribose polymérase |
| CN119365442A (zh) | 2022-06-10 | 2025-01-24 | 大鹏药品工业株式会社 | 氮杂双环式化合物的类似物 |
| WO2023238929A1 (fr) | 2022-06-10 | 2023-12-14 | 大鵬薬品工業株式会社 | Composition pharmaceutique contenant du pimitespib |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110319415A1 (en) * | 2008-08-18 | 2011-12-29 | Universit+e,uml a+ee t zu K+e,uml o+ee ln | Susceptibility to HSP90-Inhibitors |
| EP2452940B1 (fr) * | 2009-07-10 | 2014-12-17 | Taiho Pharmaceutical Co., Ltd. | Composé azabicyclo et son sel |
| RU2667509C2 (ru) * | 2013-03-14 | 2018-09-21 | Ньюлинк Джинетикс Корпорейшин | Трициклические соединения в качестве ингибиторов иммуносупрессии, опосредуемой метаболизированием триптофана |
| DK3053578T3 (da) * | 2013-09-30 | 2021-02-01 | Taiho Pharmaceutical Co Ltd | Kombinationscancerterapi ved hjælp af azabicycloforbindelse |
| CN107531707B (zh) * | 2015-05-12 | 2020-01-10 | 大鹏药品工业株式会社 | 氮杂二环式化合物的结晶 |
-
2018
- 2018-09-14 KR KR1020207006733A patent/KR102403289B1/ko not_active Expired - Fee Related
- 2018-09-14 AU AU2018333751A patent/AU2018333751B2/en not_active Ceased
- 2018-09-14 MA MA050254A patent/MA50254A/fr unknown
- 2018-09-14 SG SG11202002316PA patent/SG11202002316PA/en unknown
- 2018-09-14 CN CN201880059569.1A patent/CN111107876A/zh active Pending
- 2018-09-14 BR BR112020005100-4A patent/BR112020005100A2/pt not_active IP Right Cessation
- 2018-09-14 TW TW107132376A patent/TWI733055B/zh not_active IP Right Cessation
- 2018-09-14 CA CA3075870A patent/CA3075870A1/fr active Pending
- 2018-09-14 WO PCT/JP2018/034092 patent/WO2019054465A1/fr not_active Ceased
- 2018-09-14 RU RU2020113456A patent/RU2020113456A/ru unknown
- 2018-09-14 US US16/646,270 patent/US20200281904A1/en active Pending
- 2018-09-14 JP JP2019542296A patent/JP6931067B2/ja not_active Expired - Fee Related
- 2018-09-14 MX MX2020002886A patent/MX2020002886A/es unknown
- 2018-09-14 EP EP18855561.9A patent/EP3682900A4/fr not_active Withdrawn
-
2020
- 2020-03-12 PH PH12020500510A patent/PH12020500510A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202002316PA (en) | 2020-04-29 |
| PH12020500510A1 (en) | 2021-05-17 |
| AU2018333751B2 (en) | 2021-12-02 |
| JP6931067B2 (ja) | 2021-09-01 |
| KR20200037367A (ko) | 2020-04-08 |
| JPWO2019054465A1 (ja) | 2020-08-20 |
| RU2020113456A (ru) | 2021-10-15 |
| CA3075870A1 (fr) | 2019-03-21 |
| EP3682900A1 (fr) | 2020-07-22 |
| MX2020002886A (es) | 2020-10-01 |
| WO2019054465A1 (fr) | 2019-03-21 |
| RU2020113456A3 (fr) | 2021-10-15 |
| BR112020005100A2 (pt) | 2020-09-15 |
| TW201919708A (zh) | 2019-06-01 |
| TWI733055B (zh) | 2021-07-11 |
| AU2018333751A1 (en) | 2020-04-02 |
| CN111107876A (zh) | 2020-05-05 |
| US20200281904A1 (en) | 2020-09-10 |
| EP3682900A4 (fr) | 2021-06-16 |
| KR102403289B1 (ko) | 2022-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3370748A4 (fr) | Microbiote thérapeutique pour le traitement et/ou la prévention de l'allergie alimentaire | |
| MA45798A (fr) | Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers | |
| EP3448875A4 (fr) | Compositions pour le traitement de maladies | |
| EP3448987A4 (fr) | Compositions pour le traitement de maladies | |
| ME03314B (fr) | Thérapie basée sur l'arnm pour le traitement des maladies oculaires | |
| EP3390634A4 (fr) | Compositions et méthodes pour le traitement de maladies oculaires | |
| EP2861246A4 (fr) | Compositions et procédés pour l'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de divers troubles et maladies | |
| MA47310A (fr) | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer | |
| MA45089A (fr) | Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| EP3639833A4 (fr) | Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation | |
| MA56412A (fr) | Thérapie par l'arn messager pour le traitement des maladies articulaires | |
| EP3405191A4 (fr) | Méthodes et compositions pour le traitement de l'hyperhidrose | |
| EP3849591A4 (fr) | Méthodes et compositions pour traiter des maladies de la peau | |
| EP3634431A4 (fr) | Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b | |
| EP3986426A4 (fr) | Ciblage de l'intégrine alpha3bêta1 pour le traitement du cancer et d'autres maladies | |
| MA51136A (fr) | Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc | |
| EP3400008A4 (fr) | Compositions thérapeutiques et méthodes pour le traitement de l'hépatite b | |
| EP3741376A4 (fr) | Probiotiques pour inhiber et prévenir l'évolution de maladies rénales et compositions pour inhiber et prévenir l'évolution de maladies rénales les comprenant | |
| MA50254A (fr) | Agent prophylactique et/ou thérapeutique pour des maladies impliquant l'expression de l'ido | |
| EP3638270A4 (fr) | Compositions et méthodes pour l'amélioration d'un traitement par hyperthermie | |
| EP3331356A4 (fr) | Fragments et dérivés de la progranuline (pgrn) pour le traitement ou le soulagement des maladies lysosomales | |
| EP3398614A4 (fr) | Agent pour la prévention et/ou le traitement de la maladie d'alzheimer | |
| EP3597198A4 (fr) | Composition pour traitement des maladies articulaires, et kit contenant cette composition | |
| MA41142A (fr) | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |